Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Apr;10(7):390.
doi: 10.21037/atm-22-484.

Sacituzumab govitecan: ascending the treatment algorithm in triple negative breast cancer

Mariya Rozenblit  1 , Maryam B Lustberg  1
Affiliations
Editorial

Sacituzumab govitecan: ascending the treatment algorithm in triple negative breast cancer

Mariya Rozenblit et al. Ann Transl Med. 2022 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-484/coif). The authors have no conflicts of interest to declare.

Comment on

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
    Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Bardia A, et al. N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. N Engl J Med. 2021. PMID: 33882206 Clinical Trial.

References

    1. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 2021;384:1529-41. 10.1056/NEJMoa2028485 - DOI - PubMed
    1. Kalinsky K, Diamond JR, Vahdat LT, et al. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Ann Oncol 2020;31:1709-18. 10.1016/j.annonc.2020.09.004 - DOI - PubMed
    1. Bardia A, Tolaney SM, Punie K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol 2021;32:1148-56. 10.1016/j.annonc.2021.06.002 - DOI - PubMed
    1. Rugo HS, Tolaney SM, Loirat D, et al. Impact of UGT1A1 status on the safety profile of Sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer [abstract]. Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium. Cancer Res 2021;81: Abstract nr PS11-09. Available online: https://cancerres.aacrjournals.org/content/81/4_Supplement/PS11-09
    1. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377:914-23. 10.1016/S0140-6736(11)60070-6 - DOI - PubMed